Immunovant annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
2026
Immunovant Debt-to-Equity Ratio Growth & History (IMVT)
Immunovant's debt-to-equity ratio was 0.00 for fiscal 2026.
View full Immunovant company overviewImmunovant annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | 0.00 | −0.00 | −39.04% |
| 2025 | 2025-03-31 | 0.00 | −0.00 | −37.99% |
| 2024 | 2024-03-31 | 0.00 | −0.00 | −93.36% |
| 2023 | 2023-03-31 | 0.00 | −0.00 | −33.11% |
| 2022 | 2022-03-31 | 0.01 | −0.00 | −42.35% |
| 2021 | 2021-03-31 | 0.01 | 0.01 | — |
| 2020 | 2020-03-31 | 0.00 | — | — |
Immunovant quarterly debt-to-equity ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q4.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-03-31 | 0.00 | −0.00 | −39.04% |
| Q4 2025 | 2025-03-31 | 0.00 | −0.00 | −37.99% |
| Q3 2025 | 2024-12-31 | 0.00 | −0.00 | −85.52% |
| Q2 2025 | 2024-09-30 | 0.00 | −0.00 | −95.71% |
| Q1 2025 | 2024-06-30 | 0.00 | −0.00 | −95.87% |
| Q4 2024 | 2024-03-31 | 0.00 | −0.00 | −93.36% |
| Q3 2024 | 2023-12-31 | 0.00 | −0.00 | −87.64% |
| Q2 2024 | 2023-09-30 | 0.00 | −0.00 | −46.36% |
| Q1 2024 | 2023-06-30 | 0.00 | −0.00 | −35.81% |
| Q4 2023 | 2023-03-31 | 0.00 | −0.00 | −33.11% |
| Q3 2023 | 2022-12-31 | 0.00 | 0.00 | +70.59% |
| Q2 2023 | 2022-09-30 | 0.00 | 0.00 | +125.36% |
| Q1 2023 | 2022-06-30 | 0.00 | −0.00 | −42.91% |
| Q4 2022 | 2022-03-31 | 0.01 | −0.00 | −42.35% |
| Q3 2022 | 2021-12-31 | 0.00 | −0.01 | −74.70% |
| Q2 2022 | 2021-09-30 | 0.00 | −0.01 | −76.61% |
| Q1 2022 | 2021-06-30 | 0.01 | −0.01 | −46.68% |
| Q4 2021 | 2021-03-31 | 0.01 | 0.01 | — |
| Q3 2021 | 2020-12-31 | 0.01 | — | — |
| Q2 2021 | 2020-09-30 | 0.01 | — | — |
| Q1 2021 | 2020-06-30 | 0.02 | — | — |
| Q4 2020 | 2020-03-31 | 0.00 | — | — |
Immunovant debt-to-equity ratio trends
Over the last five fiscal years, Immunovant's debt-to-equity ratio decreased from 0.01 to 0.00, a change of −0.01. The latest reported quarter, Q4 2026, shows 0.00.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunovant source filings ↗